BRPI0407213A - Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados - Google Patents

Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados

Info

Publication number
BRPI0407213A
BRPI0407213A BR0407213-8A BRPI0407213A BRPI0407213A BR PI0407213 A BRPI0407213 A BR PI0407213A BR PI0407213 A BRPI0407213 A BR PI0407213A BR PI0407213 A BRPI0407213 A BR PI0407213A
Authority
BR
Brazil
Prior art keywords
preeclampsia
elevation
determining
marinobufagenin
employing
Prior art date
Application number
BR0407213-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Jules B Puschett
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of BRPI0407213A publication Critical patent/BRPI0407213A/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302Apparatus specially adapted for immunological test procedures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/368Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0407213-8A 2003-02-04 2004-02-02 Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados BRPI0407213A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44473003P 2003-02-04 2003-02-04
PCT/US2004/002802 WO2004071273A2 (en) 2003-02-04 2004-02-02 Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus

Publications (1)

Publication Number Publication Date
BRPI0407213A true BRPI0407213A (pt) 2006-02-07

Family

ID=32869296

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407213-8A BRPI0407213A (pt) 2003-02-04 2004-02-02 Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados

Country Status (7)

Country Link
US (1) US7439071B2 (enExample)
EP (1) EP1592967A4 (enExample)
JP (1) JP4625800B2 (enExample)
AU (1) AU2004210650C1 (enExample)
BR (1) BRPI0407213A (enExample)
CA (1) CA2515012A1 (enExample)
WO (1) WO2004071273A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402313B2 (en) 2002-07-25 2008-07-22 Charles David Adair Method for controlling preeclampsia and eclampsia
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
ATE537823T1 (de) * 2004-10-19 2012-01-15 Univ Tulane Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin
US8038997B2 (en) 2005-06-27 2011-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-marinobufagenin antibodies and methods for their use
US20070257366A1 (en) * 2006-05-03 2007-11-08 Taiwan Semiconductor Manufacturing Company, Ltd. Barrier layer for semiconductor interconnect structure
US20080299602A1 (en) * 2007-05-31 2008-12-04 Puschett Jules B Methods of Employing Vascular Leakage to Diagnose a Capillary Leak Disorder
WO2010104646A1 (en) * 2009-03-09 2010-09-16 Scott and White Memorial Hospital Method of testing a patient for hypertension and related method of treatment and test kit
US20110008904A1 (en) * 2009-07-10 2011-01-13 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for determining if a patient has a traumatic brain injury and related apparatus
US20110207154A1 (en) * 2010-01-12 2011-08-25 Scott & White Healthcare Method for determination of marinobufagenin levels and compounds employable in such method
US20160299130A1 (en) * 2015-04-09 2016-10-13 Jules B. Puschett Telocinobufagin (TCINO) in the Diagnosis and Pathogenesis of Preeclampsia, Traumatic Brain Injury and Acute Respiratory Distress Syndrome
EP3813879A1 (en) * 2018-06-21 2021-05-05 CTS Biopharma LLC Anti-marinobufagenin antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079171A (en) * 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
EP0440750A4 (en) * 1988-12-14 1991-10-09 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
GB9213934D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Chemical compounds
US5770376A (en) 1992-12-02 1998-06-23 Biomedical Sciences Research Laboratories, Inc. Method of diagnosing and treating myocardial infarction and hypertension
WO1994012210A1 (en) 1992-12-02 1994-06-09 Bagrov Alexei Y Anti-edlf antibody, composition thereof and method of diagnosing and treating cardiac arrhythmias, hypertension
US5543138A (en) * 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
GB9618931D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
US20030044856A1 (en) 1997-09-26 2003-03-06 Puschett Jules B. Method of determining volume dependent hypertension through protein reduction in phosphorylation or concentration and related apparatus
JPH11271222A (ja) * 1998-03-24 1999-10-05 Sekisui Chem Co Ltd 尿検査方法
US7794716B2 (en) * 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US10167609B1 (en) 2018-01-12 2019-01-01 Cashman Dredging & Marine Contracting Co., LLC Carouseling articulated dredge and barge

Also Published As

Publication number Publication date
AU2004210650A1 (en) 2004-08-26
EP1592967A4 (en) 2007-06-20
US20060263891A1 (en) 2006-11-23
JP2006517670A (ja) 2006-07-27
WO2004071273A2 (en) 2004-08-26
JP4625800B2 (ja) 2011-02-02
AU2004210650B2 (en) 2009-07-30
AU2004210650C1 (en) 2010-01-14
EP1592967A2 (en) 2005-11-09
WO2004071273A3 (en) 2005-02-03
CA2515012A1 (en) 2004-08-26
US7439071B2 (en) 2008-10-21

Similar Documents

Publication Publication Date Title
Nekoofar et al. pH of pus collected from periapical abscesses
Kiss et al. Age-related decline in perception of prosodic affect
EA200801071A1 (ru) Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
DE60326214D1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
MX2009003562A (es) Ensayo elisa para la deteccion de vegf.
BR112012008161B8 (pt) dispositivo que pode ser usado no corpo do usuário para prover vácuo para usos clínicos
BRPI0515758A (pt) dispositivo de ensaio de diagnóstico
ATE481032T1 (de) Vorrichtung, system und verfahren zur in-vivo- probenentnahme
CY1107901T1 (el) Μεθοδος προσδιορισμου για ασθενεια alzheimer
WO2004071427A3 (en) Screening and treatment methods for prevention of preterm delivery
CY1107715T1 (el) Διαγνωση και αγωγη του καρκινου του προστατη
WO2007092427A3 (en) Treatment of endotoxemia using endotoxin neutralizing agents
AR048031A1 (es) Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes
FR2885536B1 (fr) Composition a base d'ethers de dianhydrohexitol pour le traitement d'une matiere autre que le corps humain
JP2006517670A5 (enExample)
CY1107921T1 (el) Μεθοδος για την προγνωση της αθροιστικης επιβιωσης ασθενων
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
WO2005030265A3 (en) Optical imaging of endometriosis
BR0113646A (pt) Tratamento de distúrbios inflamatórios
ATE537823T1 (de) Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin
BRPI0508053A (pt) método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto
Fernandez-Bello Monitoring of new therapies for hemophilia
Wu Estrogen Loss Activates Memory T-Cells That Is Physiological Postpartum but Pathological Postmenopause Increasing Bone Fragility

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.